Table 2 Clinical Features of the Three Study Cohorts with Case Matched
None (n = 54) | Anti-TNF (n = 74) | Vedolizumab (n = 25) | p | |
|---|---|---|---|---|
Gender (M/F) | 29:25 | 35:39 | 13:12 | 0.76 |
Age at surgery (years) | 35 (23–49) | 30 (21–45) | 31 (22–47) | 0.31 |
BMI (kg/m2) | 23.3(19–28) | 22.7(19–26) | 21.1(19–26) | 0.15 |
Preoperative weight loss (> 10 lbs) a | 17 (35) | 23 (37) | 10 (43) | 0.79 |
Missing | 6(11) | 11(15) | 2(8) | 0.63 |
Disease duration (mos) | 61 (24–152) | 53 (20–195) | 60 (24–148) | 0.46 |
Smoking | 0.74 | |||
Never | 43 (80) | 59 (80) | 21 (84) | |
Prior | 8 (15) | 13 (17) | 4 (16) | |
Current | 3 (5) | 2 (3) | 0 | |
Disease extent | 0.89 | |||
E2 Left-sided colitis | 7 (13) | 9 (12) | 4 (16) | |
E3 Pancolitis | 47 (87) | 65 (88) | 21 (84) | |
Disease activity | 0.714 | |||
Acute | 3(5.6) | 2(2.7) | 1(4.0) | |
Chronic | 51(94.4) | 73(2.7) | 24(4.0) | |
Medication history | ||||
Steroids | 34 (68) | 48 (68) | 18 (72) | 0.92 |
6-MP or MTX | 24 (45) | 62 (84) | 20 (80) | 0.001 |
Operation type | ||||
open | 16(30) | 19(26) | 6(16) | 0.83 |
laparoscopy | 38(70) | 55(74) | 19(76) | |
Operation performed | ||||
Total abdominal colectomy +end stoma | 15 (28) | 15 (20) | 5 (20) | 0.57 |
Protectomy + IPAA with ileostomy | 39 (72) | 59 (80) | 20 (80) | |
Ileostomy repair | 46(85) | 60(81) | 19(76) | 0.61 |
Preoperative labs | ||||
Leukocyte (×103/uL) | 8.9 (6.5–12.4) | 9 (6.4–13) | 9.8 (6.9–12) | 0.79 |
Platelet (×103/uL) | 360 (281–475) | 350 (280–459) | 340 (274–487) | |
Albumin (g/dL) | 3.6 (3.3–4.0) | 3.6 (3.2–4.1) | 3.9 (3.6–4.2) | 0.87 0.25 |